COMMUNIQUÉS West-GlobeNewswire

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
30/07/2025
- Financing designed to support Phase 2 IPF trial and pipeline advancement AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel [...]
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
30/07/2025
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP [...]
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator
30/07/2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
30/07/2025
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra- [...]
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
30/07/2025
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter [...]
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
30/07/2025
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: [...]
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
30/07/2025
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad [...]
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
30/07/2025
Two Key Hires Add Significant Experience and Strengthen Vivos’ Ability to Scale Its Promising New Sleep Testing Center and Direct Patient Treatment Operations LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos [...]
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
30/07/2025
- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing - Phase 1/2 redePHine study ( NCT06839235) dose escalation ongoing with enrollment at Mayo [...]
Life Backup Plan by Galacxia, Inc Announces $45K in Funding to Expand Its AI-Powered Health and Safety App
30/07/2025
Aliso Viejo, CA, July 30, 2025 (GLOBE NEWSWIRE) -- Life Backup Plan by Galacxia, Inc , redefining how individuals and care systems manage everything from emergencies to healthcare communication, today announced $45,000 [...]
Outset Medical Names First Chief Nursing Officer
30/07/2025
Accomplished nursing executive to lead Outset’s clinical education and support programs for the dialysis nursing community SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset [...]
BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals
30/07/2025
BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay , a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its [...]
New Progyny Study Reveals Gap Between Perceptions and Realities in Women’s Health Benefits Coverage
30/07/2025
Increased awareness of expanded women’s health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- [...]
FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers
30/07/2025
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]
Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb
30/07/2025
New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use. Worcester, MA, July 30, 2025 (GLOBE NEWSWIRE) -- With heightened concern about protection from harmful airborne viruses, Vystar [...]
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
30/07/2025
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered [...]
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
30/07/2025
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the [...]
KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy
30/07/2025
RIYADH, Saudi Arabia, July 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh successfully performed a robotic Ivor Lewis esophagectomy, the first of its kind in the [...]
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
30/07/2025
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, [...]

Pages